News / Health

Test of New Dengue Vaccine Shows Promise

A boy with dengue fever receives medical oxygen while laying on a bed at the Quirino hospital in Quezon city in the suburbs of Manila, August 14, 2012.A boy with dengue fever receives medical oxygen while laying on a bed at the Quirino hospital in Quezon city in the suburbs of Manila, August 14, 2012.
x
A boy with dengue fever receives medical oxygen while laying on a bed at the Quirino hospital in Quezon city in the suburbs of Manila, August 14, 2012.
A boy with dengue fever receives medical oxygen while laying on a bed at the Quirino hospital in Quezon city in the suburbs of Manila, August 14, 2012.
Faith Lapidus
A clinical trial of a new vaccine against dengue fever shows progress toward fighting the most common mosquito-borne disease.  The drug is less successful than hoped, but seems to be effective at preventing three of the four related viruses that cause dengue.

Dengue fever increasing

Dengue fever is endemic across the tropics, with more than 2.5 billion people in 128 countries at risk. Symptoms can range from aches and fever to circulatory failure, coma and death.  Some 21,000 people die of dengue each year, and the number of cases is increasing, including outbreaks in the southeastern United States.

There is no vaccine available to prevent dengue fever.  Part of the difficulty in developing one is that there are four different but related types of the disease.  Those who recover from infection by one type gain lifetime immunity, but only against that type.  Scott Halstead, of the Dengue Vaccine Initiative, explains that they are still at risk of infection with one of the other types.

"Dengue normally produces a short acute febrile disease, sort of a flu-like disease which ends in a rash, and when you're convalescent, you have life-long immunity to the type you've been infected with, say Type 1.  But you are susceptible then to either type 2 or 3 or 4, and what we've learned is that two different infections - with say, Type 1 and Type 2 - can result in a very severe catastrophic disease called dengue hemorrhagic fever, and this occurs all over the tropical world, mostly in Asia and the American tropics," Halstead explained.

New vaccine

That is why researchers are focused on developing a so-called tetravalent vaccine, modeled on the successful yellow fever vaccine, combining weakened versions of all four types of dengue virus into a single drug. 

Halstead, who was not involved in the new clinical trial, says the pharmaceutical company, Sanofi Pasteur, took a molecular approach to creating its vaccine.

"They actually spliced the gene for each of the four dengue viruses into a yellow fever backbone.  So this is a combined vaccine called a chimera, combining the yellow fever replicative machinery and the dengue surface proteins," he said. "But it is a vaccine mixture of dengue 1, 2, 3 and 4."

In the first trial to determine whether a vaccine could actually prevent the disease, Sanofi's drug was tested in 4,000 school children in Thailand.  The children got three doses of either the vaccine or a placebo.  Spacing the shots six months apart was meant to mimic the natural immune response people develop over time.  Two years later, the vaccine seemed to have protected the children against three of the four strains, but not the most common type of the virus, which accounts for about 40 percent of severe dengue cases worldwide.

But the results show that the vaccine is safe, and technologically possible.

Although Halstead and many other dengue experts expressed disappointment that Sanofi's vaccine was not more effective, they regard it as an important step forward.

"The problem is, can we use a vaccine that only protects against three?  In my commentary that I wrote for The Lancet, I speculated that maybe, if you could really give enough of a three-component vaccine to stop transmission, you'd actually leave just one virus, and one virus all by itself won't cause dengue hemorrhagic fever.  So a lot of the really serious problems caused by dengue viruses might be controlled with a three-component vaccine," said Halstead.

Sanofi is already testing its new vaccine in large Phase 3 trials involving more than 30,000 people in 10 countries, with results expected in 2014.  A report about the Phase 2 trial, and Dr. Halstead's commentary, appear in the medical journal, The Lancet.

You May Like

In China, Mixed Signals on Ebola Controls

How authorities are monitoring at-risk individuals remains unclear, including whether there are quarantines for Chinese health workers returning from West Africa More

Video Women Voters Anxious Ahead of US Elections

Analysts say if women are focused on national security, it could be bad news for Democrats More

Solar's Future Looks Brighter

New technology and dropping prices are contributing to a surge in solar power More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Women Voters Anxious Ahead of US Electionsi
X
October 31, 2014 4:10 AM
Public opinion polls show American voters are deeply dissatisfied with their government and anxious about threats from abroad. This is especially true for a key voting group both Republicans and Democrats are trying hard to win over: women. Analysts say if women are focused on national security, it could be bad news for Democrats, with majority control of the Senate at stake. VOA’s Cindy Saine looks at the crucial role women voters will play in deciding the elections.
Video

Video Women Voters Anxious Ahead of US Elections

Public opinion polls show American voters are deeply dissatisfied with their government and anxious about threats from abroad. This is especially true for a key voting group both Republicans and Democrats are trying hard to win over: women. Analysts say if women are focused on national security, it could be bad news for Democrats, with majority control of the Senate at stake. VOA’s Cindy Saine looks at the crucial role women voters will play in deciding the elections.
Video

Video Victorious Secularists Face Challenge to Form Government in Tunisia

Official results from Tunisia show the Islamist Ennahda party has failed to win the second free election since the so-called "Arab Spring" uprising in 2011. Ennahda, which handed power to a government of technocrats pending the elections, lost out to the secular party Nidaa Tounes. Henry Ridgwell reports from London that the relatively peaceful poll offers some hope in a volatile region.
Video

Video Africa Tells its Story Through Fashion

In Africa, Fashion Week is a riot of colors, shapes, patterns and fabrics - against the backdrop of its ongoing struggle between nature and its fast-growing urban edge. How do these ideas translate into needle and thread? VOA’s Anita Powell visited this year’s Mercedes Benz Fashion Week Africa in Johannesburg to find out.
Video

Video Smugglers Offer Cheap Passage From Turkey to Syria

Smugglers in Turkey offer a relatively cheap passage across the border into Syria. Ankara has stepped up efforts to stem the flow of foreign fighters who want to join Islamic State militants fighting for control of the Syrian border city of Kobani. But porous borders and border guards who can be bribed make illegal border crossings quite easy. Zlatica Hoke has more.
Video

Video China Political Meeting Seeks to Improve Rule of Law

China’s communist leaders will host a top level political meeting this week, called the Fourth Plenum, and for the first time in the party’s history, rule of law will be a key item on the agenda. Analysts and Chinese media reports say the meetings could see the approval of long-awaited measures aimed at giving courts more independence and include steps to enhance an already aggressive and high-reaching anti-corruption drive. VOA’s Bill Ide has more from Beijing.
Video

Video After Decades of Pressure, Luxembourg Drops Bank Secrecy Rules

European Union finance ministers have reached a breakthrough agreement that will make it more difficult for tax cheats to hide their money. The new legislation, which had been blocked for years by countries with a reputation as tax havens, was approved last week after Luxembourg and Austria agreed to lift their vetoes. But as Mil Arcega reports, it doesn’t mean tax cheats have run out of places to keep their money hidden.
Video

Video Kobani Refugees Welcome, Turkey Criticizes, US Airdrop

Residents of Kobani in northern Syria have welcomed the airdrop of weapons, ammunition and medicine to Kurdish militia who are resisting the seizure of their city by Islamic State militants. The Turkish government, however, has criticized the operation. VOA’s Scott Bobb reports from southeastern Turkey, across the border from Kobani.

All About America

AppleAndroid